secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042086
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed enters up to $50M term loan with K2 HealthVentures; first tranche of $15M funded
--------------------------------------------------------------------------------

- Loan Agreement with K2 HealthVentures provides term loans up to $50M; initial $15M drawn on Aug 11, 2023.
- Additional $20M available upon clinical/regulatory milestones; up to $15M more at lenders' discretion.
- Term loan matures Aug 1, 2027; interest rate = greater of 10.95% or Prime + 2.95%.
- Lenders may convert up to $4M of principal into common shares at $4.01 per share; conversion capped at 9.985% beneficial ownership.
- Proceeds for working capital and general corporate purposes; loan secured by substantially all assets except IP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023042086/0000950170-23-042086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017023042086/mnmd-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer